Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The asthma project tezepelumab shows an effect in both eosinophilic and non-eosinophilic patients.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.